B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: a European Hematology Association Survey (EPICOVIDEHA)

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F22%3A00013463" target="_blank" >RIV/00023736:_____/22:00013463 - isvavai.cz</a>
Alternative codes found
RIV/00843989:_____/22:E0109853 RIV/65269705:_____/22:00076464 RIV/00098892:_____/22:10157296 RIV/00216224:14110/22:00128430
Result on the web
<a href="https://doi.org/10.3389/fonc.2022.992137" target="_blank" >https://doi.org/10.3389/fonc.2022.992137</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fonc.2022.992137" target="_blank" >10.3389/fonc.2022.992137</a>

Result language
angličtina
Original language name
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: a European Hematology Association Survey (EPICOVIDEHA)
Original language description
Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)